HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prevention of renal fibrosis by spironolactone in mice with complete unilateral ureteral obstruction.

AbstractPURPOSE:
Recent data suggest that aldosterone directly mediates cardiac fibrosis and hypertensive nephrosclerosis. We conducted experiments to determine whether administration of spironolactone, a mineralocorticoid receptor antagonist, reduced renal fibrosis in an experimental model of obstructive uropathy.
MATERIALS AND METHODS:
Complete unilateral ureteral obstruction (UUO) was created surgically in 8 to 10-week-old male C57BL/6 mice by placing sutures around the right ureter. Spironolactone (50 mg/kg/daily) or 1% dimethyl sulfoxide vehicle was administered by subcutaneous injection for 1 to 2 weeks, and renal fibrosis was assessed by measuring trichrome staining and type I collagen deposition in the kidney.
RESULTS:
UUO lasting 1 week was associated with minimal parenchymal damage and spironolactone had no demonstrable effect. In contrast, administration of the mineralocorticoid antagonist (8 mice) for a 2-week period significantly reduced renal fibrosis in the obstructed kidney, compared to mice given the dimethyl sulfoxide vehicle (9). The beneficial effect of spironolactone treatment was not associated with any changes in serum potassium or aldosterone concentration, or urinary concentrations of sodium or potassium.
CONCLUSIONS:
Administration of spironolactone reduced renal fibrosis in mice with UUO. These findings suggest that clinical trials are warranted to determine the efficacy of aldosterone antagonists in conjunction with angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers as renoprotective agents in patients with obstructive uropathy.
AuthorsHoward Trachtman, Adam C Weiser, Elsa Valderrama, Maria Morgado, Lane S Palmer
JournalThe Journal of urology (J Urol) Vol. 172 Issue 4 Pt 2 Pg. 1590-4 (Oct 2004) ISSN: 0022-5347 [Print] United States
PMID15371767 (Publication Type: Journal Article)
Chemical References
  • Mineralocorticoid Receptor Antagonists
  • Spironolactone
Topics
  • Animals
  • Fibrosis (prevention & control)
  • Kidney (pathology)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mineralocorticoid Receptor Antagonists (therapeutic use)
  • Spironolactone (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: